Flexible Solutions to Speed Your Molecules to Phase I Clinical Trials
When developing new pharmaceutical products, it is very important to get to Phase I clinical trial in a fast, efficient and cost-effective way. With Quick to Clinic™ for Oral Solid Dose, Thermo Fisher Scientific can deliver a drug in a phase-appropriate formulation for first-in-human studies in as little as 14 weeks from API receipt to release to clinic. This process includes one-months stability testing data to help complete regulatory submissions.
Watch this webcast to learn how to address early clinical development challenges, and how Thermo Fisher Scientific’s Quick to ClinicTM for Oral Solid Dose can help with:
- Speed and flexibility around formulation, manufacture, and clinical labeling/packaging/distribution
- Cost and time reduction
- Ensuring quality for first-in-human studies